Immutep


Entering Phase I

image Immutep Announces That ImmuFact® IMP321 Has Entered A Phase I Chemoimmunotherapy Trial In Breast Cancer.

Orsay, August 3, 2006, Immutep S.A. announced today that its lead product, ImmuFact® IMP321, has entered a Phase I chemoimmunotherapy clinical trial in metastatic breast carcinoma. ImmuFact IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response. The Company believes that this is the first time that chemoimmunotherapy, chemotherapy followed by immune stimulation, is being used in metastatic breast cancer. The study is being conducted at the René Huguenin Cancer Centre, Saint Cloud, near Paris. The design of the study is an open-label non-randomised fixed dose-escalation trial assessing IMP321 following paclitaxel. One of the Centre's main Principal Investigators, Maya Gutierrez, is leading the team carrying out the trial.

Please, click on ADOBE PDF logo to read the complete communique.

Published 08/2006 by admin@immutep.com
© 2002 Immutep, S.A.
Press Release
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
image Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
image Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - Interview Frederic Triebel with PharmaTelevision

01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...